Compare Cintas Corporation (CTAS) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs DexCom, Inc. — how do they compare? Cintas Corporation trades at $202.41 (market cap $79.86B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: Cintas Corporation is far larger — about 2.5× DexCom, Inc.'s market cap, and Cintas Corporation pays a 1.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and DexCom, Inc. for 62 Days on average.
| CTAS | DXCM | |
|---|---|---|
Market Cap | $79.86B | $31.86B |
Volume | 1,323,583 | 3,607,070 |
Sector | Industrials | Health |
52-Week High | $216.53 | $92.34 |
52-Week Low | $163.55 | $54.84 |
Typical Hold Time | 125 Days | 62 Days |
Enterprise Value | $82.33B | $31.32B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.12, up 1.99% today, with strong technical momentum above key support levels. The company demonstrates robust fundamentals with Q1 2027 revenue exceeding $3 billion for the first time, 10.9% organic growth, and raised fiscal 2027 guidance. Profit margins remain industry-leading with 50.99% gross margin and 17.82% net income margin, though valuation metrics appear elevated with a P/E of 39.67.
The outlook remains positive with consistent earnings beats and strong analyst support, though high valuation multiples and competitive pressures present risks. With 40% of analysts maintaining buy ratings and a consensus price target of $234.60 representing 16.6% upside, the stock offers growth potential but requires monitoring of margin sustainability and market multiple compression risks.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
